Clarius Group, LLC Adaptive Biotechnologies Corp Transaction History

Clarius Group, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 25, 2023	SELL	$6.26 - $9.34 $43,356 - $64,688	-6,926 Reduced 22.52%	23,824 $182,000
Q3 2022 Oct 24, 2022	BUY	$6.5 - $12.67 $23,465 - $45,738	3,610 Added 13.3%	30,750 $219,000
Q2 2022 Aug 10, 2022	BUY	$6.4 - $14.73 $105,350 - $242,470	16,461 Added 154.14%	27,140 $220,000
Q4 2021 Feb 02, 2022	SELL	$25.17 - $36.85 $503,400 - $737,000	-20,000 Reduced 65.19%	10,679 $300,000
Q2 2021 Aug 06, 2021	BUY	$32.22 - $44.59 $182,977 - $253,226	5,679 Added 22.72%	30,679 $1.25 Million
Q4 2020 Jan 15, 2021	SELL	$45.01 - $65.47 $206,865 - $300,900	-4,596 Reduced 15.53%	25,000 $1.48 Million
Q1 2020 Apr 24, 2020	SELL	$16.96 - $34.16 $169,600 - $341,599	-10,000 Reduced 25.26%	29,596 $822,000
Q4 2019 Jan 22, 2020	BUY	$24.56 - $32.8 $972,477 - $1.3 Million	39,596 New	39,596 $1.17 Million

202

146M

68.8K

42.5K

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $849M
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

Get notified when there are updates to the investment portfolio of Clarius Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Clarius Group, LLC with notifications on news.